Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Semjonow

Showing results (41-50 of 102) with videos related to

Pageof 11
Sort By:
Urologic Oncology|May 9, 2006
Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liabilityAnders Larsson, Gunnar Ronquist, Christian Wülfing, et al.
BJU International|March 31, 2015
The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 yearsMartin Boegemann, Carsten Stephan, Henning Cammann, et al.
The Prostate|March 28, 2003
Expression-patterns of the RNA component (hTR)and the catalytic subunit (hTERT) of human telomerase in nonneoplastic prostate tissue, prostatic intraepithelial neoplasia, and prostate cancerOlaf Bettendorf, Bernhard Heine, Sören Kneif, et al.
BMC Medical Informatics and Decision Making|November 17, 2010
Clinical map document based on XML (cMDX): document architecture with mapping feature for reporting and analysing prostate cancer in radical prostatectomy specimensOkyaz Eminaga, Reemt Hinkelammert, Axel Semjonow, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 16, 2016
Correlation of Intraprostatic Tumor Extent with ⁶⁸Ga-PSMA Distribution in Patients with Prostate CancerKambiz Rahbar, Matthias Weckesser, Sebastian Huss, et al.
Anticancer Research|July 2, 2010
Negative predictive value of systematic ultrasound-guided prostate biopsy: which tumours do we miss?Thomas Köpke, Frank Oberpenning, Olaf Bettendorf, et al.
The Prostate|November 19, 2016
Blind Biobanking of the Prostatectomy Specimen: Critical Evaluation of the Existing Techniques and Development of the New 4-Level Tissue Extraction Model With High Sampling EfficacyYuri Tolkach, Okyaz Eminaga, Fabian Wötzel, et al.
International Journal of Cancer|July 15, 2004
Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implicationsKlaus Jung, Michael Lein, Carsten Stephan, et al.
BJU International|February 21, 2014
Prostate cancers detected on repeat prostate biopsies show spatial distributions that differ from those detected on the initial biopsiesOkyaz Eminaga, Reemt Hinkelammert, Mahmoud Abbas, et al.
The International Journal of Biological Markers|May 9, 2018
Discordant prostate specific antigen test results despite WHO assay standardizationMartin Boegemann, Christian Arsov, Boris Hadaschik, et al.
Pageof 11

Showing results (41-50 of 102) with videos related to

Sort By:
Pageof 11
Urologic Oncology|May 9, 2006
Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liabilityAnders Larsson, Gunnar Ronquist, Christian Wülfing, et al.
BJU International|March 31, 2015
The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 yearsMartin Boegemann, Carsten Stephan, Henning Cammann, et al.
The Prostate|March 28, 2003
Expression-patterns of the RNA component (hTR)and the catalytic subunit (hTERT) of human telomerase in nonneoplastic prostate tissue, prostatic intraepithelial neoplasia, and prostate cancerOlaf Bettendorf, Bernhard Heine, Sören Kneif, et al.
BMC Medical Informatics and Decision Making|November 17, 2010
Clinical map document based on XML (cMDX): document architecture with mapping feature for reporting and analysing prostate cancer in radical prostatectomy specimensOkyaz Eminaga, Reemt Hinkelammert, Axel Semjonow, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 16, 2016
Correlation of Intraprostatic Tumor Extent with ⁶⁸Ga-PSMA Distribution in Patients with Prostate CancerKambiz Rahbar, Matthias Weckesser, Sebastian Huss, et al.
Anticancer Research|July 2, 2010
Negative predictive value of systematic ultrasound-guided prostate biopsy: which tumours do we miss?Thomas Köpke, Frank Oberpenning, Olaf Bettendorf, et al.
The Prostate|November 19, 2016
Blind Biobanking of the Prostatectomy Specimen: Critical Evaluation of the Existing Techniques and Development of the New 4-Level Tissue Extraction Model With High Sampling EfficacyYuri Tolkach, Okyaz Eminaga, Fabian Wötzel, et al.
International Journal of Cancer|July 15, 2004
Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implicationsKlaus Jung, Michael Lein, Carsten Stephan, et al.
BJU International|February 21, 2014
Prostate cancers detected on repeat prostate biopsies show spatial distributions that differ from those detected on the initial biopsiesOkyaz Eminaga, Reemt Hinkelammert, Mahmoud Abbas, et al.
The International Journal of Biological Markers|May 9, 2018
Discordant prostate specific antigen test results despite WHO assay standardizationMartin Boegemann, Christian Arsov, Boris Hadaschik, et al.
Pageof 11